Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study

Recruiting now · Phase 1/Phase 2

Conditions studied: Giant Cell Tumor of Bone

In brief

ICG fluorescence imaging will be applied during the intralesional curettage of giant cell tumor of bone in the limbs. This study aims to preliminarily explore whether ICG fluorescent-guided curettage could find small residual tumors and reduce the recurrence rate of tumor.

Key facts

Study ID

NCT06647901

Run by

Tang Xiaodong

People needed

45

Starts

2024-08-23

Expected to finish

2028-08-31

Last updated by the study team

2024-10-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• . Aged 18-65.
• Biopsy confirmed giant cell tumor of bone.
• The lesions located in the limbs.
• This operation is the initial treatment.
• Denosumab and diphosphonates are not used before surgery.
• Planned operation is intralesional curettage and filling bone defects with bone cement.
• Preoperative bone scan and thin layer (layer thickness ≤3.5mm) chest CT plain scan confirmed that the lesion is a single occurrence without metastasis.
• Subjects fully understand the benefits and risks of this experiment and are still willing to participate and sign the informed consent.

You may not qualify if…

• . Known allergy to iodine contrast, indocyanine green or bone cement.
• . Severe hepatic and renal insufficiency.
• . During pregnancy or lactation.
• . Have other malignant tumors and are receiving related medical treatment.

Where it is running

• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.